Short communicationComparative binding of etretinate and acitretin to plasma proteins and erythrocytes
References (8)
- et al.
In vitro interactions of the aromatic retinoids Ro 10-9359 (etretinate) and Ro 10-1670 (acitretin), its main metabolite, with human serum lipoproteins and albumin
Biochim Biophys Acta
(1990) - et al.
Binding of retelliptine, a new antitumoral agent, to serum proteins and erythrocytes
Biochem Pharmacol
(1990) - et al.
Human serum albumin. Spectroscopic studies of binding and proximity relationships for fatty acids and bilirubin
J Biol Chem
(1979) - et al.
Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients
Pharmacol Toxicol
(1988)
There are more references available in the full text version of this article.
Cited by (22)
Anti-HBV activity of retinoid drugs in vitro versus in vivo
2019, Antiviral ResearchCitation Excerpt :To that end we compared typical clinical exposures reported for the most promising retinoid drugs with our EC50s. Note that these clinical retinoids are highly protein bound in plasma (>99.9%) (Thatcher and Isoherranen, 2009; Urien et al., 1992) such that a protein-binding adjustment should be applied to the EC50s. However, we found that these drugs were also highly protein bound in our cell culture medium (>99%) and that addition of 50% human serum to our PHH medium did not significantly increase the EC50s (data not shown).
Guidelines for the use of acitretin in psoriasis
2013, Actas Dermo-SifiliograficasPrediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution
2002, Journal of Pharmaceutical SciencesDetermination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins
2000, Journal of Pharmaceutical SciencesBinding of artemether and lumefantrine to plasma proteins and erythrocytes
1999, European Journal of Pharmaceutical Sciences
Copyright © 1992 Published by Elsevier Inc.